Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDX-3315 and NDX-3324 in Healthy Adult Participants and Patients With Eosinophilic Esophagitis
NCT05757856Phase 2Completed
- Sponsor
- NexEos Bio
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Technetium-99m radiolabeled heparin and NDX-3324 in eosinophilic esophagitis (EoE) (2 arms), sponsored by NexEos Bio. Primary endpoints: Proportion of participants with Adverse Events up to 3 Weeks, Peak eosinophil counts per high-power field (HPF) and 2 more. Started Jan 2023; status: completed.
02
Drugs
Technetium-99m radiolabeled heparinNDX-3324
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05757856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757856.